InvestorsHub Logo
Followers 17
Posts 1224
Boards Moderated 1
Alias Born 06/30/2014

Re: None

Sunday, 09/19/2021 11:56:42 AM

Sunday, September 19, 2021 11:56:42 AM

Post# of 140476
I know. You guess.

https://www.upcounsel.com/corporate-officer-duties

https://www.stimmel-law.com/en/articles/corporate-officers-duties-and-fiduciary-responsibilities

Question Mc's efforts all you want. Many questioned the lack of communication from Mc in the distant past. Now he's communicating as much as possible, and promoting the company. Then we get your retort. No surprise. What, too much, too soon? Need more time to complain? That addresses officer responsibilities. Now, we can move on.

You have presented a valid point of concern. A possible raise. However ill timed b/c of the amount of cash on-hand, still a possibility. From which there are alternate views besides the ONLY one you've presented for consideration. The sp rose unexpectedly, and pretty significantly prior to the last raise. I'll make a guess, and expect the sp to rise again, IF another raise is done. You can speculate, and short from the increased sp if you desire. Judging from the desperation and pleading for participation in the recent past, shorting hasn't worked out too well. Too much risk for me. If another venture fund - friendly to MDT, jumped in and moves the sp even higher. Again, as I've pointed out, no one can predict what will happen 10 minutes from now, tomorrow, next week or next month.

I've addressed your statement and will again. "So far it seems nobody has an interest in enos…..including Medtronic.
That’s why they licensed the IP." It's called a strategy, when applied using situational awareness. There are many paths to acquire a company, and the process by which MDT has done it +60 times is clear. They don't announce a BO - as their first and only communication. Your recollection of the details of the MDT growth business model is severely lacking. I, and many here have provided the most recent outcomes from the Mazor BO, and the quotes from Martha as to the "mistakes" made during that project. I'm providing real factual information addressing your thesis, as to why it's highly unlikely that you're correct. You're opinion, no facts in support of the alternative argument(s).

I'm sure you understand the process of dating, before engagement, then marriage. It's the same process of discovery, for high-dollar acquisitions. The ONLY way to address the risk of the unknown, and mitigate the adverse effects to the down-side, is to increase the amount of time spent performing due diligence. Time is all there is to permit further investigation. While your faux premise that "no one is interested," may be valid, it's incomplete, and not an entirely objective statement from which the entire view is presented. How surprising...

While you may hope your messages have the desired negative effect(s) of the share price, and thus a smaller value for a BO, I'd bet your efforts will be in vain. I question why you make such an extensive and lengthy effort, for an investment that you purport to have shares.

And it's no surprise to anyone that reads my messages that you've never answered the question(s) regarding how MDT makes a SP RAS device to compete against TMDI/ENOS from 15 patents. Or how they jump ahead 4-5 years in development, or the risk of developing the additional components and USPTO approvals, additional $350M funding, and the fall-out from the BoD of not addressing the ease from which a unique SP RAS device may be acquired. Which supports the entire statement as to how MDT will conduct business now, and in the future.

If you have a problem, and the money to solve the problem, then you don't have a problem. This premise is only valid if MDT wishes to compete in the RAS medical device market segment, and compete for RAS medical device revenue for the next 20-30 years. Such a ridiculous premise. Unless the CEO and CoB has specifically stated that exact strategy for moving ahead of the competitive business environment, instead of developing competitive products organically.

Ignoring the question does not make it go away. It only makes the question more important and germane to the outcome of the present business environment.

Good luck to all. Regards,BK.